|
|
Substance Name: Roxithromycin [USAN:INN:BAN:JAN]
RN: 80214-83-1
UNII: 21KOF230FA
InChIKey: RXZBMPWDPOLZGW-XMRMVWPWSA-N
Note
- Semisynthetic derivative of erythromycin. It is concentrated by human phagocytes and is bioactive intracellularly. While the drug is active against a wide spectrum of pathogens, it is particularly effective in the treatment of respiratory and genital tract infections.
Molecular Formula
- C41-H76-N2-O15
Molecular Weight
- 837.0504
- All
- Classifications
- Links to Resources
- Names & Synonyms
- Registry Numbers
- Structure Descriptors
- Toxicity
- Physical Properties
Classification Codes
- Anti-Bacterial Agents
- Anti-Infective Agents
- Antibacterial
* denotes mobile formatted website
Links to Resources
NLM Resources (File Locators)
Other Resources (Internet Locators)
Search for this InChIKey on the Web
Names and Synonyms
Name of Substance
- Roxithromycin
- Roxithromycin [USAN:INN:BAN:JAN]
MeSH Heading
- Roxithromycin
Synonyms
- BRN 4286925
- CCRIS 3461
- Erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime)
- Erythromycin, 9-(O-((2-methoxyethoxy)methyl)oxime)
- Roxithromycin
- Roxithromycine
- Roxithromycine [French]
- Roxithromycinum
- Roxithromycinum [Latin]
- Roxitromicina
- Roxitromicina [Spanish]
- RU 28965
- RU 965
- Rulide
- UNII-21KOF230FA
Systematic Names
- 9-(O-((2-Methoxyethoxy)methyl)oxime)erythromycin
- Erythromycin, 9-(O-((2-methoxyethoxy)methyl)oxime)
- Erythromycin, 9-(O-((2-methoxyethoxy)methyl)oxime), (9E)-
Registry Numbers
CAS Registry Number
- 80214-83-1
FDA UNII
- 21KOF230FA
System Generated Number
- 0080214831
Structure Descriptors
InChI
1S/C41H76N2O15/c1-15-29-41(10,49)34(45)24(4)31(42-53-21-52-17-16-50-13)22(2)19-39(8,48)36(58-38-32(44)28(43(11)12)18-23(3)54-38)25(5)33(26(6)37(47)56-29)57-30-20-40(9,51-14)35(46)27(7)55-30/h22-30,32-36,38,44-46,48-49H,15-21H2,1-14H3/b42-31+/t22-,23-,24+,25+,26-,27+,28+,29-,30+,32-,33+,34-,35+,36-,38+,39-,40-,41-/m1/s1InChIKey
RXZBMPWDPOLZGW-XMRMVWPWSA-NSmiles
CC[C@H]1OC(=O)Toxicity
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD50 | oral | 0.2gm/kg (200mg/kg) | Drugs in Japan Vol. -, Pg. 1471, 1995. | |
mouse | LD50 | intraperitoneal | 148mg/kg (148mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 33, Pg. 787, 1991. | |
mouse | LD50 | oral | 665mg/kg (665mg/kg) | Drugs in Japan Vol. -, Pg. 1471, 1995. | |
rat | LD50 | intraperitoneal | 171mg/kg (171mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 33, Pg. 787, 1991. | |
rat | LD50 | oral | 830mg/kg (830mg/kg) | LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) | Chemotherapy Vol. 36(Suppl, |
Physical Properties
Physical Property | Value | Units | Temp (deg C) | Source |
---|---|---|---|---|
log P (octanol-water) | 2.750 | (none) | EST | |
Atmospheric OH Rate Constant | 3.42E-10 | cm3/molecule-sec | 25 | EST |
Physical property data is provided to ChemIDplus by SRC, Inc.